Bio-Techs
We wrote a note a few weeks ago saying that we were moving
into the bio-tech space for a few reasons, seasonality and favorable chart
patterns the two main reasons (Biotech's
Getting Ready to Break-Out).
This past week we saw the bio-tech ETF (IBB) break above
$300 and we decided to build a position. We decided to buy Direxion Daily
S&P Biotech Bull 3X ETF (LABU) @ $56.55. We are sitting on 27% profits and
will hold to see a pull-back and support. Any support above $55 will entice us
to further increase our position.
From Business
Insider, “The Nasdaq Biotechnology
Index (NBI) surged 9.2% over the five days, its biggest increase since the
week of the election. Portola Pharmaceuticals and Clovis Oncology led the
charge for the 162-company gauge, both climbing more than 55%.
In addition, an
exchange-traded fund tracking the gauge absorbed more than $700 million during
the three days ended Friday, the biggest inflow since early November for a
period of that length.”
“While a significant
portion of post-election stock market gains have resulted from optimism around
proposed political policies, biotech drove returns the old-fashioned way: by
getting good news.
According to recent
reports from Kaiser Health News and Politico, the Trump
administration is preparing an executive order that's shaping up
to be favorable to drug companies. On Tuesday, The New York
Times reported on the contents of a draft of the executive order, reaffirming
the administration's likely more relaxed, industry-friendly stance on drug pricing.
That marks a stark
departure from the anti-drugmaker rhetoric floated by Donald Trump in recent
months, with the president even going as far as to say back in January that
biotech companies are "getting away with murder."
It's the latest twist
and turn for biotech stocks, which have been taken for a wild ride since
the election. The NBI rose a whopping 12% in the week following November 8
amid expectations that Trump would have a positive effect on the group, which
was blasted by Hillary Clinton on multiple occasions on the campaign trail.
But it wasn't that
simple, as Trump made comments over time that led investors to believe that he
too was targeting drugmakers. For instance, on March 21 said that he wanted to
slip drug pricing into the GOP Obamacare replacement plan. The NBI dropped
2.8% that day.
While the future for
drugmakers may have looked bleak at times, the recent surge in index was
actually foreshadowed by options traders. As of May 18, they were paying the
lowest premium since October 2013 to protect against losses in the NBI,
relative to hedges on the S&P 500, Bloomberg data show. That's an extremely
bullish signal.
Now that things have
been looking up for biotech, investors are starting to pay a higher
premium to protect gains.”
“Beyond the recent
news flow, investors may also be buying biotech shares in preparation for the
earnings recovery the sector is expected to enjoy in the second half of
the year.
Drugmakers will grow
profits by 5.7% in the fourth quarter, lifting its full-year 2017 earnings
expansion to 4.8%, according to estimates compiled by Bloomberg. While that
will lag the broader S&P 500, it's a welcome sign for an industry just
finding its legs again after some turbulence.”
Energy
Back in May we decided to take a few positions in the Energy
sector. This trade turned out to be a mess with oil prices entering bear market
conditions and energy names suffering greatly because of it (Looking
at a Few Trades in the Energy Sector).
Brent crude prices are approaching the 50% Fibonacci
retracement from the early 2016 lows. The green shaded area in the chart below
could act as some support.
That said, we do not have high hopes of this sector
rebounding anytime soon and we’ll probably cut our losses if XLE breaks $62.50
to the downside.
Last November, the
Organization of Petroleum Exporting Countries tried to solve this by agreeing
to lower production. But this was not enough, and Libya, Nigeria and Iran —
three members that weren't part of the agreement — have raised their
production.
So have US shale-oil
producers, who this week extended a record-long streak of adding drilling
rigs.
And so, the supply
side failed to avert a 4% slide in oil prices this week to the cheapest levels
since OPEC agreed to cut output in November.
Strategists at Bank of
America Merrill Lynch are skeptical that higher demand would be the solution.
"It is hard not
to notice some cyclical red flags" that risk counteracting higher oil
prices, said Sabine Schels, a commodity strategist, in a note with colleagues
on Friday.
"While most
investors blame supply for today's low oil prices, demand has also failed to
improve at the speed required to rebalance the global oil market. Looking
into 2H17, we now doubt that demand growth will accelerate sufficiently and see
downside risks to our forecasts of 1.3 million b/d in both 2H17 and 2018. In
the absence of a mirroring supply response, softer consumption could push 2018
balances into surplus. Put differently, demand will not break the current
downward price momentum for now."
Any takers?
Oil demand in the
first quarter slowed and was weaker than expected, Schels said, after examining
demand growth by region.
The strategists
initially pointed to a number of temporary factors like a warmer-than-usual
winter in the US and India's decision to void the highest denominations of its
currency. But as demand weakness extended into the second quarter, it became
clear that these weren't the only reasons.
Worse still, Schels
said, is that the demand weakness is spreading to markets that are usually
strong including the US and China. "This suggests that cyclical, rather
than solely transient, factors are perhaps also at play here."”
“Beyond that,
the global economic picture doesn't suggest that countries are going to be
demanding more oil soon.
"Clearly, the
uncertainty around tax reform has started to dampen sentiment and confidence,
with negative consequences for investment and hiring decisions," Schels
said. "In Asia Pacific and Japan, economic data and inflation has also
started to roll over. In Latin America, the situation in Brazil is u nstable
leading us to halve our GDP growth expectations for next year to 1 .5
%."
China provides the
clearest example of a cyclical slowdown, Schels said, amid a softening in
industrial production and electricity generation.
BofAML forecasts a
slowdown in China's economic growth and thinks that could lead to a slowdown in
imports of crude oil.”
“Central banks could
also be complicit in keeping oil demand by forging ahead with raising interest
rates. Schels noted that it becomes harder to finance consumption of oil when
interest rates rise. Also, if higher rates lead to a stronger dollar,
emerging-market countries that are big consumers of energy products could face
higher costs.
"Tighter money at
a time of weaker activity poses deflationary risks and spillover to the real
economy," Schels wrote. “
Gasoline
Gasoline prices are rolling over. The commodity broke
through support near $1.45 on higher volume. The next level of support looks to
be near $1.28. This represents another 10% to the downside. United States
Gasoline (UGA) ETF is thinly traded but offers an opportunity to capitalize on
the weakness. I’m not sure if there is an opportunity to short this ETF but I
noticed that it does trade options. I may pull the trigger and purchase some
put options if there is adequate liquidity.
I’m not sure yet how to participate to the downside (as I
don’t trade gasoline futures) but I’ll be doing some research this coming week
to see if there’s a way to make money with this trade. Preferably we’d like to
see a bit of strength in the commodity and a failure to recapture support.
Defensive Sector Trades
Defensive sectors appear to be in play. The chart below
depicts the PowerShares S&P 500 High Beta ETF (SPHB) against the PowerShares
S&P 500 Low Volatility ETF (SPLV). The trend clearly favors lower volatility
defensive stocks. The high beta portfolio is trading below its 50-day EMA while
the low vol ETF is solidly above its 50-day EMA.
Since the Trump rally started to lose steam back in
February/March we are seeing trends that the market is taking a more cautionary
stance towards the economy.
We’re seeing additional evidence of this skepticism with the
aggressive flattening of the yield curve of late. The steepening of the yield
curve that happened post-election has now retraced back to where it was prior
to President Trump being elected. As long as this economic skepticism remains
in place, we will expect the low volatility defensive stocks to outperform the
higher beta names.
Health Care has exploded this week. This is good for us as
we build a value position in the sector (XLV) back in November in the $68
range. Like the bio-tech trade, we’ll wait for a pull-back and see where
support settles in and most likely add to our positions.
Consumer Staples
The consumer staples sector is not cheap by any means but we
believe it could offer a nice shorter-term swing trade opportunity. From the
chart below we are seeing a solid bullish trend in the sector as depicted by
several of its exponential moving averages. The Consumer Staples Select Sector
SPDR ETF (XLP) has dropped to its 50-day moving average that provided support
earlier in the year. It is also sitting near support from its breakout point.
Also note that the RSI (30) has consistently remained above
50 for the year and the RSI (5) is under 30 (oversold). This oversold situation
in a larger uptrend has offered several short-term trading opportunities in the
past.
Since 1998, there have been only been roughly 50 trading
opportunities out of over 4600 observations (1.7% of the time) where the RSI
(30) was above 50 and the RSI (5) was below 30. The two, three, four and five
day returns upon this occurrence have been exceptional, offering annualized
returns in excess of 30% vs. roughly 5% when this condition is not in place.
These swing trades have been profitable nearly 70% of the time.
For those looking for a swing trade opportunity this is as
good a set-up that we can find in these market conditions.
In the graphic below, I have provided the near-term return
profile for XLP when this RSI condition has been met. All-in-all I like the
risk/reward profile of this trade.
Utilities
Another defensive sector that had broken out is the
utilities sector. Similar to the consumer staples sector, it too has an RSI
(30) above 50 and an RSI (5) below 30. This is a rare occurrence and has led to
near-term sector outperformance. While I ran the back test for return results,
I’m just not a buyer of utilities now and rather keep assets deployed in the
health care, bio-tech and consumer staples sectors.
Joseph S. Kalinowski, CFA
Email: joe@squaredconcept.net
Twitter: @jskalinowski
Facebook: https://www.facebook.com/JoeKalinowskiCFA/Blog: http://squaredconcept.blogspot.com/
Tumblr: trader-rants
No part of this report may be reproduced in any manner
without the expressed written permission of Squared Concept Asset Management,
LLC. Any information presented in this report is for informational
purposes only. All opinions expressed in this report are subject to
change without notice. Squared Concept Asset Management, LLC is a
Registered Investment Advisory and consulting company. These entities may have
had in the past or may have in the present or future long or short positions,
or own options on the companies discussed. In some cases, these positions
may have been established prior to the writing of the report.
The above information should not be construed as a
solicitation to buy or sell the securities discussed herein. The
publisher of this report cannot verify the accuracy of this information.
The owners of Squared Concept Asset Management, LLC and its affiliated
companies may also be conducting trades based on the firm’s research
ideas. They also may hold positions contrary to the ideas presented in
the research as market conditions may warrant.
This analysis should not be considered investment advice and
may not be suitable for the readers’ portfolio. This analysis has been written
without consideration to the readers’ risk and return profile nor has the
readers’ liquidity needs, time horizon, tax circumstances or unique preferences
been considered. Any purchase or sale activity in any securities or other
instrument should be based upon the readers’ own analysis and conclusions. Past
performance is not indicative of future results.